Source Paper
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi, Roger C. Pai, Sharon Fong, Susan Leung, David A. Lawrence et al.
Journal of Clinical Investigation • 1999
Tumor Xenograft Prevention Study
Objective: To assess the ability of Apo2L (Apo2 ligand/TRAIL) treatment to reduce tumor incidence when administered shortly after tumor xenograft injection in athymic mice
This is a Tumor Xenograft Prevention Study protocol using mouse as the model organism. The procedure involves 5 procedural steps, 4 materials. Extracted from a 1999 paper published in Journal of Clinical Investigation.
Model and subjects
mouse • athymic • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Tumor xenograft injection • Apo2L treatment initiation • Monitor tumor development
Primary readouts
- Tumor incidence reduction
- Tumor cell apoptosis induction
- Tumor progression suppression
- Survival improvement
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Tumor xenograft injection
Inject tumor cells into athymic mice to establish xenograft tumors
Note: Timing of injection is critical as Apo2L treatment follows shortly after
View evidence from paper
“Treatment of athymic mice with Apo2L shortly after tumor xenograft injection markedly reduced tumor incidence”
Apo2L treatment initiation
Administer Apo2L treatment shortly after tumor xenograft injection
Note: Treatment timing is critical for tumor incidence reduction
View evidence from paper
“Treatment of athymic mice with Apo2L shortly after tumor xenograft injection markedly reduced tumor incidence”
Monitor tumor development
Assess tumor incidence and progression in treated mice
Note: Measure tumor incidence as primary outcome
View evidence from paper
“Treatment of athymic mice with Apo2L shortly after tumor xenograft injection markedly reduced tumor incidence”
Assess tumor cell apoptosis and progression
Evaluate tumor cell apoptosis induction, tumor progression suppression, and survival improvement
Note: Multiple outcome measures assessed
View evidence from paper
“Apo2L treatment of mice bearing solid tumors induced tumor cell apoptosis, suppressed tumor progression, and improved survival”
Optional combination therapy
In some mice, combine Apo2L treatment with chemotherapeutic drugs 5-fluorouracil or CPT-11
Note: Combination therapy showed synergistic effects
View evidence from paper
“Apo2L cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation”